News & Events
- September 22, 2017
-
September 11, 2017
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide
September 11, 2017 TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Path), CHDI Foundation, Inc. (CHDI), and The Clinical Data Interchange Standards Consortium (CDISC) announce the availability of a draft Huntington’s disease (HD) Therapeutic Area User Guide (TAUG-HD v1.0) for public review. The TAUG-HD v1.0... - August 17, 2017
-
August 17, 2017
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J. The MSOAC Approach to Developing Performance Outcomes to Measure and Monitor Multiple Sclerosis Disability. Multiple Sclerosis Journal. 2017 Aug 11;1352458517723718.
-
July 28, 2017
Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson’s disease clinical trials: a disease progression modeling analysis
Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K, Stephenson DT, Romero K, on behalf of the Critical Path for Parkinson’s (CPP) Parkinson’s Disease Modeling and Simulation Working Group. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson’s Disease Clinical Trials: A Disease Progression Modeling Analysis: Dopamine Transporter Imaging Enrichment Biomarker. Clinical and Translational Science. 2017 Jul 27.
